Grifols "sell"

12/29/06 - Ibersecurities

LONDON, December 29 (newratings.com) - Analysts at Ibersecurities maintain their "sell" rating on Grifols SA (OZT). The target price is set to €6.2.

In a research note published yesterday, the analysts mention that the FDA has approved the license for the company to distribute the new generation of Intravenous Immunoglobulin (IVIG) under the name of Flebogamma (R) DIF in the US. This would be produced at Grifols’ new plant that was constructed in 2004, the analysts say. Ibersecurities expects positive newsflow related to this in 1Q07.